




Contents lists available at ScienceDirect

Contraception

journal homepage: www.elsevier.com/locate/contraception

Special Article

Society of Family Planning Committee Statement: Telemedicine in family planning care part 1 – Background and overarching principles^{☆,☆☆}

Rajita Patil^{a,*}, Divya Dethier^b, Montida Fleming^c, Emily Godfrey^d, Julia E. Kohn^e, with the assistance of Jennifer Chin, Bhavik Kumar, Jennifer Lesko, April Lockley, Shawana S. Moore, and Laurie Ray on behalf of the Clinical Affairs Committee, and Robert Johnson

^a University of California, Los Angeles, David Geffen School of Medicine, Department of Obstetrics and Gynecology, Los Angeles, CA, United States

^b Kaiser Permanente San Francisco, Obstetrics and Gynecology, San Francisco, CA, United States

^c UCSF Family and Community Medicine, Department of Family and Community Medicine, San Francisco, CA, United States

^d University of Washington Department of Family Medicine, Seattle, WA, United States

^e Columbia Mailman School of Public Health, Department of Population and Family Health, New York, NY, United States

ARTICLE INFO

Article history:

Received 5 December 2024

Received in revised form 9 April 2025

Accepted 11 April 2025

Keywords:

Abortion

Contraception

Family planning

Telehealth

Telemedicine

Virtual

ABSTRACT

Telemedicine is an effective modality for remote family planning care delivery. Telemedicine increases reach, reduces barriers to care, and facilitates person-centered care. As the demand for telemedicine increases, evidence-based guidance is crucial for optimal practice. This clinical guidance series offers evidence-informed, person-centered, and equity-driven recommendations to enhance telemedicine delivery of contraceptive services and medication abortion in the US. Providing care via telemedicine may not be for everyone, and thus, clinicians should take a person-centered approach to ensure telemedicine meets the needs of the person receiving care. Ensuring that telemedicine remains accessible, regardless of whether a person also requires in-person clinical services, is essential to person-centered family planning care. Telemedicine family planning services should be integrated across practice settings and codesigned with persons from marginalized communities to ensure services are linguistically appropriate, equitable, and accessible. Clinicians should engage in implementation and advocacy efforts that combat health, digital, and structural inequities contributing to disparities in telemedicine family planning care access. Telemedicine family planning care should address the privacy and confidentiality of the person receiving care. Telemedicine family planning care clinicians should be familiar with their state, regional, and institutional laws or regulations regarding abortion care and, more broadly, telemedicine before providing care. Where uncertainty exists, clinicians should consult a lawyer experienced in telemedicine and abortion care. The companion documents, *Society of Family Planning Clinical Recommendation: Telemedicine for abortion and contraception part 2 – Contraception* and *Society of Family Planning Clinical Recommendation: Telemedicine for abortion and contraception part 3 – Abortion*, build upon this document and focus on actionable clinical recommendations.

© 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

^{*} Conflicts of interest: Montida Fleming, MD, provides clinical consultation services for Hey Jane, a virtual direct-to-patient telemedicine company that provides telemedicine medication abortion and contraceptive care. The other authors have no conflicts of interest to report. SFP receives no direct support from pharmaceutical companies or other industries to produce clinical recommendations.

^{**} Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclaimer: This publication is designed as a resource to assist clinicians in providing family planning care. It should not be considered inclusive of all proper treatments or serve as the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations, considering individual circumstances, may be appropriate. This publication reflects the best-available evidence at the time of publication, recognizing that continued research or major changes in the practice environment may impact future recommendations and should be evaluated for incorporation into care. Clinical guidance, grounded in evidence-based research, is distinct from legal requirements and restrictions governing family planning care. Medical recommendations do not vary based on practice location. However, abortion is not legal in all states and circumstances, and this document is not intended to aid in or otherwise advocate for unlawful care. Any updates to this document can be found on <https://societyfp.org/clinical/clinical-guidance-library/>. SFP and its contributors provide the information contained in this publication "as is" and without any representations or warranties, express or implied, of any kind, whether of accuracy, reliability, or otherwise.

^{*} Corresponding author.

E-mail address: rpatil@mednet.ucla.edu (R. Patil).

<https://doi.org/10.1016/j.contraception.2025.110914>

0010-7824/© 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Please cite this article as: R. Patil, D. Dethier, M. Fleming et al., Society of Family Planning Committee Statement: Telemedicine in family planning care part 1 – Background and overarching principles, *Contraception*, <https://doi.org/10.1016/j.contraception.2025.110914>

1. Background

1.1. Purpose

Telemedicine is an effective modality for remote family planning care delivery. While telemedicine may not be suitable for all family planning needs, when appropriate, telemedicine increases reach, reduces barriers to care, and facilitates person-centered care. It enables health care facilities to respond to the growing demand for services while maintaining access to in-person care [1–3]. Clinicians who provide abortion care via telemedicine appreciate its scheduling flexibility, increased patient access, reduced scheduling delays and cancellations, and seeing persons earlier in pregnancy [4]. Telemedicine also reaches people who live farther away from abortion facilities, thereby increasing service access in more rural areas of the US [3,5–11].

Telemedicine medication abortion has demonstrated significant benefits by reducing the burdens of cost, travel, time, and the stigma associated with abortion, particularly for those living in rural areas or in states requiring two appointments for abortion care [9,11,12]. Remote follow-up for medication abortion decreases the average estimated cost per person by 39%, mostly due to forgoing ultrasonography [13]. Telemedicine can address barriers related to initiating or refilling contraception prescriptions, especially for individuals who have difficulty accessing or affording clinic appointments or are unable to take time off from work or school [14]. For postpartum persons, telemedicine improves attendance rates for postpartum visits, which increases the likelihood of obtaining postpartum contraception [15]. Moreover, persons receiving contraceptive counseling via telemedicine are equally likely to choose a contraceptive method as those seeking in-person care [16,17].

Telemedicine can enhance person-centered care. Satisfaction rates among persons receiving care for telemedicine abortion are high, ranging from 80–100%, with dissatisfaction rates under 2.5% [4,13,18–27]. For abortion care, satisfaction stems from the removal of barriers, enhancement of the relationship between the clinician and the person receiving care, autonomy, and a sense of control over the process [1,11,13,18,19,22,24,26,28–35]. For contraceptive care, persons from diverse backgrounds and with unique needs are highly satisfied with the availability of telemedicine contraceptive care [36–45]. Persons feel that they have more time with the clinician to consider contraceptive options, address side effects, switch methods, and feel less pressure to make an immediate decision [46,47].

Telemedicine in family planning care has increased significantly in recent years due in part to the COVID-19 pandemic, which led to rapid innovation in health care delivery models to reduce in-person visits [48,49]. During COVID-19, 71% of independent abortion facilities chose telemedicine for abortion follow-up and 41% for pre-abortion consultation [50]. Many facilities adopted no-test medication abortion protocols, omitting in-person exams, ultrasonography, and pre-abortion testing, such as Rh testing. Others introduced curbside and mail-order delivery of abortion medications [50,51]. Similarly, the percentage of US-based reproductive health care clinicians offering telemedicine contraceptive care rose from 11% pre-pandemic to nearly 80% during the pandemic [52]. Telemedicine in family planning care continues to rise post-pandemic, making evidence-based guidance essential for optimal practice [53].

This clinical guidance series provides evidence-informed, person-centered, and equity-driven recommendations to enhance the management of and access to contraceptive services and medication abortion via telemedicine within the US. It's companion documents, *Society of Family Planning Clinical Recommendation: Telemedicine in family planning care part 2 – Contraception* and *Society of Family Planning Clinical Recommendation: Telemedicine in family planning care part 3 – Abortion*, build upon this document and focus on actionable clinical recommendations [54,55].

1.2. Definitions

The exact definitions of telemedicine and telehealth vary. *Telemedicine* falls under *telehealth*, which includes a broad range of virtual nonclinical services such as contraceptive reminder programs or mobile health (mHealth) [56]. This guidance defines *telemedicine* as providing clinical care virtually via synchronous and asynchronous approaches within the formal health care system. In synchronous care, persons receiving care and clinicians engage in a virtual visit simultaneously, either “direct-to-clinic” (also known as “site-to-site”), where a person goes to a clinical facility and communicates with a clinician who is off-site via teleconference, or “direct-to-patient”, in which persons receive care in their home or another place of their choosing [57]. Both audio-video and audio-only visits are acceptable for virtual synchronous care. Clinicians may use them to provide care according to the preference of the person receiving care. An audio-only option should be available if technical difficulties with video conferencing arise [58,59]. In asynchronous care, persons first provide the relevant medical information via a questionnaire. A clinician then reviews this information and provides treatment virtually if the person receiving care is eligible. Asynchronous telemedicine services can enhance access, offering greater convenience and timeliness by eliminating the need for synchronous phone or video calls [60–62]. *Telemedicine care* can be entirely virtual or a hybrid of virtual and in-person. Clinicians providing this care include licensed physicians, nurses, and advanced practice clinicians.

Telemedicine medication abortion differs from self-managed abortion, in which a person ends a pregnancy outside of the formal health care system and may involve a range of interactions with community support, clinicians, or both [63,64]. Please see the *Society of Family Planning Interim Clinical Recommendations: Self-managed abortion* for further information on this topic [63].

2. Committee statements

2.1. Clinicians should take a person-centered approach to ensure telemedicine meets the needs of the person receiving care.

Although telemedicine family planning satisfaction rates are high, clinicians should understand individual preferences, acceptability, and needs to deliver person-centered care. Successful telemedicine contraceptive care should align with best-practices, accommodating a person's complex and nuanced views and framing each method according to their overall health and well-being [65]. Overall people greatly value their choice in service modality and consider it an important aspect of meeting their healthcare needs [66].

For telemedicine medication abortion, remote consultations that omit pretreatment ultrasonography and exam are considered acceptable and trustworthy due to time and cost savings, privacy, avoiding uncomfortable procedures, and not having to view ultrasound images [19,67–69]. Remote follow-up is also highly acceptable [70–73]. However, some express anxiety about not having ultrasonography confirmation of the pregnancy [19].

Some persons value being in the same room as the clinician for abortion visits, while others experience stigma or uncomfortable power dynamics with the clinician in an in-person clinical setting [19,38]. Those undergoing a telemedicine medication abortion are likely to choose it again for a future abortion and recommend it to a friend [21,22,68]. Studies comparing in-person and telemedicine medication abortion experiences show no overall difference in preparedness of the person receiving care, including their expectations for pain and bleeding. In some studies, the telemedicine experience exceeds expectations [25,68,74].

For telemedicine contraceptive care, persons prefer having multiple options for obtaining contraception, including in-person, telemedicine, direct-to-patient telemedicine, and pharmacies, when

clinically appropriate (Table 1) [75]. Despite the preference of persons receiving care for and the appropriateness of telephone-only telemedicine for prescribing contraception, some health care systems require video visits due to system regulations, clinical preferences, and higher insurance reimbursement rates [39,46]. Where permissible, clinician preferences for video visits should be balanced against the broader accessibility of telephone-based care [36,37,46]. Preferences can vary by community setting. For example, some school-based health center studies show a preference for telemedicine, while others prefer in-person care [76,77]. The content of the counseling visit may also impact preferences. One study from New York reports a preference for telemedicine for “basic” contraception options counseling but in-person care for more “complex” topics like pregnancy and preconception [38].

It is important to consider the unique needs of different populations, such as persons seeking contraception postabortion, pregnant and postpartum persons, adolescent and young adults (AYA), persons with disabilities, and those living in rural areas, when providing contraceptive counseling. Contraception counseling is often offered during in-person abortion visits (i.e. “integrated counseling”), which can be challenging due to operational and time constraints. The person receiving care may not want to discuss contraception at the time of their abortion [78]. Virtual individual or group contraceptive counseling sessions scheduled ahead of an in-person abortion visit are feasible and acceptable [79,80]. One study found persons opting for telemedicine contraceptive counseling separate from the abortion encounter were more likely to be non-White, have had difficulty obtaining contraception in the past, and not be using contraception at the time of conception [80]. Telemedicine counseling before in-person abortion care is more strongly associated with choosing and receiving a desired long-acting reversible contraceptive (LARC) method at the time of in-person abortion care compared to integrated counseling. However, one study indicates that persons who chose LARC during telemedicine medication abortion may be less likely to obtain a LARC method after completing the abortion, while another study shows no difference [17,81]. These differences in outcomes of contraceptive choice and provision between in-person and telemedicine medication abortion care underscores the importance of providing both telemedicine and in-person options for those seeking contraception at the time of abortion.

Most AYA perceive synchronous video-based telemedicine care for contraceptive services as acceptable and accessible, and their high levels of digital competency may make them particularly well-suited to telemedicine [42,82]. Screening protocols can help identify AYA at risk of sexual abuse or exploitation in remote contraception services [83].

However, access to a private space to discuss sexual and reproductive health needs is crucial and may lead to a preference for asynchronous or in-person care [42,43,84]. Insurance status can also limit AYA access to telemedicine contraceptive care [85].

The diversity of preferences across populations, clinical contexts, and care modalities highlights the importance of adaptable service models. In this context, ensuring that telemedicine remains accessible, regardless of whether a person also requires in-person clinical services, is essential to person-centered family planning care.

2.2. Telemedicine abortion and contraceptive services should be integrated across practice settings and codesigned with persons from marginalized communities to ensure services are linguistically appropriate, equitable, and accessible.

Facilities that already use telemedicine technology for different appointment types can readily apply this technology for telemedicine medication abortion [86]. Facilities not already using telemedicine may require additional training with the technology and guidelines for online consultations [30]. Facilities should use platforms that support obtaining patient signatures to meet the Risk Evaluation and Mitigation Strategy (REMS) requirements for mifepristone administration [86]. For contraceptive visits, self-selection of the encounter type is an important factor in care quality assessments [36,47]. Telemedicine appointments are more successful when persons receive instructions on how to join their visit before the telemedicine visit [87].

Key factors for successful implementation include a supportive institution [88], a facility champion, formal or informal mentoring by organizations within and outside the facility who can help overcome challenges such as meeting regulatory compliance and current standards of care [89,90], and creating standing operating procedures with clear guidelines [30,91]. Challenges include effectively marketing the telemedicine services and raising awareness about their availability [1].

Language is a critical consideration for telemedicine care globally, as linguistic diversity poses challenges across many countries. In the US, almost 10% of the population has limited English proficiency [92]. Most platforms require a degree of English proficiency to navigate scheduling and accessing the visit [1,93]. Cultural values and beliefs around health care also influence how persons and communities prefer to access reproductive health care and may limit telemedicine's benefit [94]. To ensure equitable access, health care facilities should codesign telemedicine care during the implementation process with persons receiving care [95].

Table 1

Summary of contraceptive services suitable for telemedicine versus services that typically require in-person visits

Contraceptive services that are suitable for telemedicine provision	Contraceptive services that typically require in-person visits
Counseling about IUD self-removal; video or telephone coaching for IUD self-removal	IUD removal (if patient is unable to or unwilling to attempt self-removal)
Prescription (initiation or continuation) of oral contraceptive pills, transdermal patch, or vaginal ring	Contraceptive implant removal
Provision of oral emergency contraception	Contraceptive implant or IUD insertion
Prescription (initiation or continuation) of self-administered subcutaneous DMPA-SC, possible video coaching for DMPA-SC self-administration	Administration of DMPA-IM
Prescription of barrier and other pericoital methods (including diaphragm, spermicides, contraceptive sponge, condoms, vaginal pH regulator gel)	Symptoms concerning for ectopic pregnancy, including pregnancy with IUD in situ
Counseling before IUD and contraceptive implant insertion, removal, or replacement, including counseling about extended use of IUDs and contraceptive implants	Suspected IUD expulsion or nonpalpable contraceptive implant (if symptomatic and/or if there is concern for pregnancy)
Evaluation and potential management of some contraceptive issues or side effects (e.g., heavy or unscheduled bleeding)	Some contraceptive issues or side effects (if severe symptoms)
Consultation for permanent contraception Contraceptive counseling, including counseling about fertility-awareness-based methods	Initiation of permanent contraception

DMPA-IM, depot medroxyprogesterone acetate – intramuscular; DMPA-SC, depot medroxyprogesterone acetate – subcutaneous; IUD, intrauterine device. Reprinted from Society of Family Planning Clinical Recommendations: Contraceptive care in the context of pandemic response [58].

2.3. Clinicians should engage in implementation and advocacy efforts that combat health, digital, and structural inequities contributing to disparities in telemedicine family planning care access.

State-level abortion bans are not evidence-based and do not improve the safety or efficacy of clinical care [96,97]; However, they have severely limited in-person abortion care, forcing farther travel to obtain an abortion. Telemedicine family planning care has the potential to increase access for those who must travel the longest distances and who face the most barriers, including people of color; those without insurance, with low income, facing food insecurity, or living in rural locations; AYA; incarcerated individuals; people with disabilities; immigrants; and gender diverse individuals [8,98].

Research suggests persons who are younger, have at least one medical condition, whose first language is not English, who identify as Black, and others from under-resourced and rural communities have limited access to and are less likely to use telemedicine services for abortion care and contraceptive counseling [5,99-103]. Over 50% of abortions in the US are provided to Black and Latine/X individuals, more than 70% are to people under 30%, and 75% are to people with low incomes [104,105]. This demonstrates the disproportionate impact that challenges to telemedicine medication abortion access may have on these groups [106]. Internet access and digital literacy challenges also reduce telemedicine access and usability [107-111]. Connectivity issues remain barriers for some [37,47,112]. Up to 30% of Americans still experience internet connectivity problems, and those with lower incomes or less formal education are less likely to have reliable internet access [113]. AYAs, who account for 6% of all abortions in the US, encounter additional obstacles when trying to use telemedicine services [105]. These barriers include lack of awareness, stigma, financial and insurance constraints, and confidentiality concerns related to parental notification and consent requirements [85,114,115].

Despite the rapid adoption and innovation of telemedicine by many health care clinicians, facilities in under-resourced areas still face significant implementation barriers, exacerbating the inequity in telemedicine care provision [116]. Smaller outpatient facilities and those serving many persons with publicly-funded health insurance often do not offer telemedicine due to lower reimbursement rates compared to in-person visits, as well as the higher costs and effort required to establish the necessary infrastructure [93,117-120].

2.4. Telemedicine family planning care should address the privacy and confidentiality of the person receiving care.

Privacy. Clinicians should conduct telemedicine visits in a private space and address confidentiality and privacy concerns, especially for vulnerable populations such as AYAs or those experiencing intimate partner violence. Access to a safe and private space for persons receiving care to discuss sexual and reproductive health needs is crucial and may lead to a preference for asynchronous or in-person care [42-44,61].

Confidentiality. Persons receiving care and clinicians express concern about confidentiality in telemedicine [9,38,121]. Concerns about the security of personal health data when utilizing telemedicine services are especially significant for individuals residing in states with restrictive abortion laws who seek abortion care in other states [122]. Clinicians should document only clinically relevant information to minimize risk to the person receiving care and make notes confidential. Digital encryption is a crucial security measure to safeguard protected health information (PHI). Telemedicine providers should use Health Insurance Portability and Accountability Act (HIPAA)-compliant platforms that limit or prohibit automatic medical record sharing with other health systems.

Additional confidentiality considerations for AYAs must account for local laws on parental notification and consent for family

planning services. Clinicians may find these requirements more uncertain in a telemedicine context [84,123]. While many states allow for confidential contraceptive services without parental consent or notification, insurance factors may limit confidentiality [84,124]. Laws for abortion care are more complex, with many states requiring parental involvement, though most allow a judicial bypass for court-approved abortion decisions [125].

2.5. Clinicians should be familiar with their state, regional, and institutional laws and regulations regarding abortion care and, more broadly, telemedicine before providing care. Where uncertainty exists, clinicians should consult a lawyer experienced in telemedicine and abortion care.

Some states specifically prohibit the use of telemedicine for abortion care despite its demonstrated safety, efficacy, and acceptability [126]. Other states that protect abortion access have instituted "shield laws", which provide certain protections for clinicians in that state to provide abortion care to persons living in other states, including states that ban or restrict abortion. Some shield laws provide protections for telemedicine care rendered across state lines to persons who are in states that ban abortions. Other shield laws strictly apply to clinicians providing care for persons who have traveled from banned states to receive an abortion in a state where it is legal [127].

When providing telemedicine across state lines, clinicians render care in the state where the person receiving care is physically located. Therefore, they must practice under the laws of and, generally, be licensed in the state where the person receiving care is located, unless there is a cross-state waiver or a shield law allowing them to prescribe medication abortion in states where they are not licensed. Waivers providing exceptions for licensing requirements for most states have ended, since they were primarily in place during the COVID-19 Public Health Emergency [128].

3. Continued discussion

During the development of this document, we identified multiple areas where further discussion, research and consensus are needed, and we invite further exploration:

- Insurance coverage of and policy barriers to telemedicine for contraception and abortion care.
- Evaluation of barriers and facilitators to telemedicine to address health care access inequity, particularly among adolescents and young adults (including parental consent and privacy concerns) and rural and underserved communities.
- Development and evaluation of culturally and linguistically appropriate telemedicine services.
- Exploration of emerging technologies (AI, mobile health apps) to enhance telemedicine contraceptive care.
- Patient preferences for and satisfaction with counseling and education methods for telemedicine medication abortion.

4. Summary of statements

- Clinicians should take a person-centered approach to ensure telemedicine meets the needs of the person receiving care.
- Telemedicine abortion and contraceptive services should be integrated across practice settings and codesigned with persons from marginalized communities to ensure services are linguistically appropriate, equitable, and accessible.
- Clinicians should engage in implementation and advocacy efforts that combat health, digital, and structural inequities contributing to disparities in telemedicine family planning care access.

- Telemedicine family planning care systems should address the privacy and confidentiality of the person receiving care.
- Clinicians should be familiar with their state, regional, and institutional laws and regulations regarding abortion care and, more broadly, telemedicine before providing care. Where uncertainty exists, clinicians should consult a lawyer experienced in telemedicine and abortion care.

5. Sources

A series of clinical questions was developed by the authors and reviewed by representatives from the Society of Family Planning's (SFP) Clinical Affairs Committee. We searched PubMed, Ovid Medline, Cochrane Library of Clinical Trials, Embase, and the Turning Research Into Practice (TRIP) database to identify relevant articles published between 2003 and July 2024. Search terms included, but were not limited to abortion, contraception, family planning, telehealth, telephone, telemedicine, video, and virtual. The search was restricted to articles published in the English language. We also identified studies by reviewing the references of relevant articles and clinical guidelines published by organizations or institutions with related recommendations, such as the Centers for Disease Control and Prevention, the American College of Obstetricians and Gynecologists, and SFP. The content of and references cited in relevant product labels and Food and Drug Administration (FDA) prescribing information were also considered when developing critical statements on topics involving medications. When relevant evidence was not available or too limited to inform practice, the expert opinion of clinicians with complex family planning expertise was used to develop the critical statements.

6. Intended audience

This Committee Statement is intended for SFP members, family planning and sexual and reproductive health service clinicians, family planning and reproductive health researchers, consumers of family planning care, advocates, and policymakers.

Authorship

This Committee Statement was prepared by Rajita Patil, MD; Divya Dethier, MD; Montida Fleming, MD; Emily Godfrey, MD, MPH; and Julia E. Kohn, PhD, MPA, with the assistance of Jennifer Chin, MD, MS; Bhavik Kumar, MD, MPH; Jennifer Lesko, MD, MPH; April Lockley, DO; Shawana S. Moore, PhD, DNP, APRN, WHNP-BC, FNAP, FAAN, FNPWH; and Laurie Ray, DNP, WHNP-BC on behalf of the Clinical Affairs Committee, and Robert Johnson. It was reviewed and approved by Clinical Affairs Committee members on behalf of the SFP Board of Directors.

Acknowledgment

The American College of Nurse-Midwives endorses this document. The authors would like to thank Margaret Villalonga, Senior Clinical Affairs Manager at SFP, for her hard work on this document.

References

- [1] Ruggiero SP, Seymour JW, Thompson T-A, Kohn JE, Snow JL, Grossman D, et al. Patient and provider experiences using a site-to-site telehealth model for medication abortion. *mHealth* 2022;8. <https://doi.org/10.21037/MHEALTH-22-12>
- [2] Grindlay K, Grossman D. Telemedicine provision of medical abortion in Alaska: through the provider's lens. *J Telemed Telecare* 2017;23:680–5. <https://doi.org/10.1177/1357633x16659166>
- [3] Grossman D, Grindlay K, Buchacker T, Potter JE, Schmetzmann C. Changes in service delivery patterns after launching telemedicine provision of medication abortion in Iowa. *Contraception* 2010;82:205–6. <https://doi.org/10.1016/j.contraception.2010.04.109>
- [4] Endler M, Lavelanet A, Cleeve A, Ganatra B, Gomperts R, Gemzell-Danielsson K. Telemedicine for medical abortion: a systematic review. *BJOG Int J Obstet Gynaecol* 2019;126:1094–102. <https://doi.org/10.1111/1471-0528.15684>
- [5] Fiastro AE, Zheng Z, Ruben MR, Gipson J, Godfrey EM. Telehealth vs in-clinic medication abortion services. *JAMA Netw Open* 2023;6:e2331900. <https://doi.org/10.1001/jamanetworkopen.2023.31900>
- [6] Beardsworth KM, Doshi U, Raymond E, Baldwin MK. Miles and days until medical abortion via TelAbortion versus clinic in Oregon and Washington, USA. *BMJ Sex Reprod Health* 2022;48:e38–43. <https://doi.org/10.1136/bmjshr-2020-200972>
- [7] Jones Rachel K, Gibson Candace, Philbin Jesse. The number of brick-and-mortar abortion clinics drops, as US abortion rate rises: new data underscore the need for policies that support providers. *Guttmacher Institute*; 2024.
- [8] Koenig LR, Becker A, Ko J, Upadhyay UD. The role of telehealth in promoting equitable abortion access in the United States: a spatial analysis (Preprint). *JMIR Public Health Surveill* 2023. <https://doi.org/10.2196/45671>
- [9] Sundstrom B, DeMaria AL, Ferrara M, Smith E, McInnis S. "People are struggling in this area:" a qualitative study of women's perspectives of telehealth in rural South Carolina. *Women Health* 2020;60:352–65. <https://doi.org/10.1080/03630242.2019.1643814>
- [10] Jones RK, Gibson C, Philbin J. The number of brick-and-mortar abortion clinics drops, as US abortion rate rises: new data underscore the need for policies that support providers. 2024.
- [11] Kaller S, Daniel S, Raifman S, Biggs MA, Grossman D. Pre-abortion informed consent through telemedicine vs. in person: differences in patient demographics and visit satisfaction. *Womens Health Issues* 2021;31:227–35. <https://doi.org/10.1016/j.whi.2021.02.007>
- [12] Ehrenreich K, Kaller S, Raifman S, Grossman D. Women's experiences using telemedicine to attend abortion information visits in Utah: a qualitative study. *Womens Health Issues* 2019;29:407–13. <https://doi.org/10.1016/j.whi.2019.04.009>
- [13] Vanetti A, Catarino R, Yaron M. Remote self-assessment follow-up for medical termination of pregnancy at Geneva University Hospitals: an insight into its acceptability, success rate and costs. *Swiss Med Wkly* 2021;151:w20531. <https://doi.org/10.4414/smw.2021.20531>
- [14] Grindlay K, Grossman D. Prescription birth control access among U.S. women at risk of unintended pregnancy. *J Womens Health* 2016;25:249–54. <https://doi.org/10.1089/jwh.2015.5312>
- [15] Arias MP, Wang EY, Hamm RF, Leitner K, Sannah T, Keegan M, et al. IMPACT (IMPact on Postpartum Care by Telehealth) Study: a retrospective cohort study. *Am J Obstet Gynecol* 2022;226:S67. <https://doi.org/10.1016/j.ajog.2021.11.133>
- [16] Das KJH, Fuerst M, Brown C, Lesko J. Use of postpartum contraception during coronavirus disease 2019 (COVID-19): a retrospective cohort study. *Int J Gynecol Obstet* 2021;155:64–71. <https://doi.org/10.1002/ijgo.13805>
- [17] Woofter R, Patil R, Sudhinaraset M, Gipson J. Long-acting reversible contraception preference and initiation among clinic-based and telemedicine medication abortion patients at one academic health system in California. *Contraception* 2025;110838. <https://doi.org/10.1016/j.contraception.2025.110838>
- [18] Grindlay K, Lane K, Grossman D. Women's and providers' experiences with medical abortion provided through telemedicine: a qualitative study. *Womens Health Issues* 2013;23:e117–22. <https://doi.org/10.1016/j.whi.2012.12.002>
- [19] Koenig LR, Ko J, Valladares ES, Coeytaux FM, Wells E, Lyles CR, et al. Patient acceptability of telehealth medication abortion care in the United States, 2021–2022: a cohort study. *Am J Public Health* 2024;114:241–50. <https://doi.org/10.2105/AJPH.2023.307437>
- [20] Chong E, Shochet T, Raymond E, Platais I, Anger HA, Raidoo S, et al. Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic. *Contraception* 2021;104:43–8. <https://doi.org/10.1016/j.contraception.2021.03.019>
- [21] Tsereteli N, Mamatsashvili L, Tsertsvadze G, Tsereteli T, Platais I. Telemedicine medical abortion service in Georgia: an evaluation of a strategy with reduced number of in-clinic visits. *Eur J Contracept Reprod Health Care* 2023;28:141–6. <https://doi.org/10.1080/13625187.2023.2170710>
- [22] Raymond E, Chong E, Winikoff B, Platais I, Mary M, Lotarevich T, et al. TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States. *Contraception* 2019;100:173–7. <https://doi.org/10.1016/j.contraception.2019.05.013>
- [23] Thompson T-A, Sonalkar S, Butler JL, Grossman D. Telemedicine for family planning: a scoping review. *Obstet Gynecol Clin North Am* 2020;47:287–316. <https://doi.org/10.1016/j.ogc.2020.02.004>
- [24] Grossman D, Grindlay K, Buchacker T, Lane K, Blanchard K. Effectiveness and acceptability of medical abortion provided through telemedicine. *Obstet Gynecol* 2011;118:296–303. <https://doi.org/10.1097/AOG.0b013e318224d110>
- [25] Endler M, Petro G, Gemzell Danielsson K, Grossman D, Gomperts R, Weinryb M, et al. A telemedicine model for abortion in South Africa: a randomised, controlled, non-inferiority trial. *The Lancet* 2022;400:670–9. [https://doi.org/10.1016/S0140-6736\(22\)01474-X](https://doi.org/10.1016/S0140-6736(22)01474-X)
- [26] Fix L, Seymour JW, Sandhu MV, Melville C, Mazza D, Thompson T-A. At-home telemedicine for medical abortion in Australia: a qualitative study of patient experiences and recommendations. *BMJ Sex Reprod Health* 2020;46:172–6. <https://doi.org/10.1136/bmjshr-2020-200612>
- [27] Schmidt-Hansen M, Cameron S, Lohr PA, Hasler E. Follow-up strategies to confirm the success of medical abortion of pregnancies up to 10 weeks' gestation: a systematic review with meta-analyses. *Am J Obstet Gynecol* 2020;222:551–563.e13. <https://doi.org/10.1016/j.ajog.2019.11.1244>

- [28] Anger HA, Raymond EG, Grant M, Haskell S, Boraas C, Tocce K, et al. Clinical and service delivery implications of omitting ultrasound before medication abortion provided via direct-to-patient telemedicine and mail in the U.S. *Contraception* 2021;104:659–65. <https://doi.org/10.1016/j.contraception.2021.07.108>
- [29] Peña M, Figueroa Flores K, Muñoz Ponce M, Facio Serafin D, Camarillo Zavala AM, Ruiz Cruz C, et al. Telemedicine for medical abortion service provision in Mexico: a safety, feasibility, and acceptability study. *Contraception* 2022;114:67–73. <https://doi.org/10.1016/j.contraception.2022.06.009>
- [30] Somfun OD, Constant D, Endler M. The acceptability of implementing telemedicine for early medical abortion in South Africa: a substudy to a randomized controlled trial. *SSM – Qual Res Health* 2023;3. <https://doi.org/10.1016/j.ssmqr.2023.100241>
- [31] Kerestes C, Delafield R, Elia J, Chong E, Kaneshiro B, Soon R. "It was close enough, but it wasn't close enough": a qualitative exploration of the impact of direct-to-patient telemedicine abortion on access to abortion care. *Contraception* 2021;104:67–72. <https://doi.org/10.1016/j.contraception.2021.04.028>
- [32] Aiken ARA, Starling JE, Gomperts R. Factors associated with use of an online telemedicine service to access self-managed medical abortion in the US. *JAMA Netw Open* 2021;4. <https://doi.org/10.1001/jamanetworkopen.2021.11852>
- [33] Srinivasulu S, Nyandak D, Fiastrro AE, MacNaughton H, Tressan A, Godfrey EM. Telehealth medication abortion in primary care: a comparison to usual in-clinic care. *J Am Board Fam Med JABFM* 2024;37:295–302. <https://doi.org/10.3122/jabfm.2023.230178R1>
- [34] Upadhyay UD, Grossman D. Telemedicine for medication abortion. *Contraception* 2019;100:351–3. <https://doi.org/10.1016/j.contraception.2019.07.005>
- [35] Johnson DM, Madera M, Gomperts R, Aiken ARA. The economic context of pursuing online medication abortion in the United States. *SSM – Qual Res Health* 2021;1. <https://doi.org/10.1016/j.ssmqr.2021.100003>
- [36] Freeman E, Paul R, Dorsey M, Madden T. Comparison of interpersonal quality of contraceptive counseling delivered via telehealth versus in person. *Contraception* 2023;128. <https://doi.org/10.1016/j.contraception.2023.110129>
- [37] Stifani BM, Avila K, Levi EE. Telemedicine for contraceptive counseling: an exploratory survey of US family planning providers following rapid adoption of services during the COVID-19 pandemic. *Contraception* 2021;103:157–62. <https://doi.org/10.1016/j.contraception.2020.11.006>
- [38] Srinivasulu S, Manze MG, Jones HE. "I totally didn't need to be there in person": New York women's preferences for telehealth consultations for sexual and reproductive healthcare in primary care. *Fam Pr* 2023;40:402–6. <https://doi.org/10.1093/fampra/cmab102>
- [39] Song B, Boulware A, Wong ZJ, Huang I, Whitaker AK, Hasselbacher L, et al. "This has definitely opened the doors": provider perceptions of patient experiences with telemedicine for contraception in Illinois. *Perspect Sex Reprod Health* 2022;54:80–9. <https://doi.org/10.1363/psrh.12207>
- [40] Yarger J, Van Liefde D, Quirarte A, Elmes S, Dojiri SS, Jackson AV, et al. 90. "I didn't know before that you can get birth control this way": developing a tool to teach young people about telehealth for contraception...2022 Society for Adolescent Health and Medicine (SAHM) Annual Meeting – caring for adolescents in a post-pandemic world, March 9–12, 2022, Sheraton San Diego Hotel & Marina San Diego, California. *J Adolesc Health* 2022;70:S47–8. <https://doi.org/10.1016/j.jadohealth.2022.01.185>
- [41] Kampire HT, Cloutier J, Dallaire M, Plourde S, Labrecque M. Men prefer vasectomy consultation by telephone: a survey of vasectomized men. *Can J Urol* 2022;29:11307–11.
- [42] Diaz MF, Colleen G, Gruver R, Gold MA, Maier M, Usseglio J, et al. Providing contraceptive health services to adolescents and young adults by telemedicine: a scoping review of patient and provider perspectives. *J Pediatr Adolesc Gynecol* 2022;35:575–84. <https://doi.org/10.1016/j.jpjag.2022.05.003>
- [43] Vallée CA, Dubuc E. Pediatric and adolescent gynecology population's satisfaction with telemedicine consultation on contraception during the COVID-2019 pandemic. *J Pediatr Adolesc Gynecol* 2022;35:225. <https://doi.org/10.1016/j.jpjag.2022.01.085>
- [44] Monaco AE, Westhoff CL. Evaluating virtual visits for contraceptive counseling: an exploratory study using the Person-Centered Contraceptive Counseling (PCCC) scale, a patient-reported outcome measure. *Contraception* 2024;137:110443. <https://doi.org/10.1016/j.contraception.2024.110443>
- [45] Simons H, Athilat S, Kochhar S. Effectiveness and patient centeredness of contraceptive care delivered through telehealth - preliminary results from a post-visit patient survey. *Contraception* 2023;127:110235. <https://doi.org/10.1016/j.contraception.2023.110235>
- [46] Stifani BM, Smith A, Avila K, Boos EW, Ng J, Levi EE, et al. Telemedicine for contraceptive counseling: patient experiences during the early phase of the COVID-19 pandemic in New York City. *Contraception* 2021;104:254–61. <https://doi.org/10.1016/j.contraception.2021.04.006>
- [47] Shin RJ, Yao M, Akesson C, Blazel M, Mei L, Brant AR. An exploratory study comparing the quality of contraceptive counseling provided via telemedicine versus in-person visits. *Contraception* 2022;112:86–92. <https://doi.org/10.1016/j.contraception.2022.02.004>
- [48] Koonin L, Hoots B, Tsang C. Trends in the use of telehealth during the emergence of the COVID-19 pandemic—United States, January–March 2020. *CDC*; 2020.
- [49] The Adoption of Telehealth 2021.
- [50] Upadhyay UD, Schroeder R, Roberts SCM. Adoption of no-test and telehealth medication abortion care among independent abortion providers in response to COVID-19. *Contracept X* 2020;2. <https://doi.org/10.1016/j.conx.2020.100049>
- [51] Raymond EG, Grossman D, Mark A, Upadhyay UD, Dean G, Creinin MD, et al. Commentary: no-test medication abortion: a sample protocol for increasing access during a pandemic and beyond. *Contraception* 2020;101:361–6. <https://doi.org/10.1016/j.contraception.2020.04.005>
- [52] Comfort AB, Rao L, Goodman S, Raine-Bennett T, Barney A, Mengesha B, et al. Assessing differences in contraceptive provision through telemedicine among reproductive health providers during the COVID-19 pandemic in the United States. *Reprod Health* 2022;19:1–13. <https://doi.org/10.1186/s12978-022-01388-9>
- [53] #WeCount Report 7: April 2022 to March 2024. Society of Family Planning; 2024. <https://doi.org/10.46621/878086iuzegt>
- [54] Patil R, Dethier D, Fleming M, Godfrey E, Kumar B, Kohn JE, with the assistance of Ray L, et al. Society of Family Planning Clinical Recommendation: Telemedicine in family planning care part 2 - Contraception. *Contraception* n.d.
- [55] Patil R, Dethier D, Fleming M, Godfrey E, Kumar B, Kohn JE, with the assistance of Ray L, et al. Society of Family Planning Clinical Recommendation: Telemedicine in family planning care part 3 - Abortion. *Contraception* n.d.
- [56] Office of the National Coordinator for Health Information Technology. What is telehealth? How is telehealth different from telemedicine? | HealthIT.gov n.d. (<https://www.healthit.gov/faq/what-telehealth-how-telehealth-different-telemedicine>) (accessed July 26, 2024).
- [57] Fok WK, Mark A. Abortion through telemedicine. *Curr Opin Obstet Gynecol* 2018;30:394–9. <https://doi.org/10.1097/GCO.0000000000000498>
- [58] Stifani BM, Madden T, Micks E, Moayed G, Tarleton J, Benson LS. Society of Family Planning Clinical Recommendations: contraceptive care in the context of pandemic response. *Contraception* 2022;113:1–12. <https://doi.org/10.1016/j.contraception.2022.05.006>
- [59] Dunlop H, Sinay A-M, Kerestes C. Telemedicine abortion. *Clin Obstet Gynecol* 2023;66:725–38. <https://doi.org/10.1097/GRF.00000000000000818>
- [60] Smith NK, Cleland K, Wagner B, Trussell J. "I don't know what I would have done." Women's experiences acquiring ulipristal acetate emergency contraception online from 2011 to 2015. *Contraception* 2017;95:414–8. <https://doi.org/10.1016/j.contraception.2016.10.004>
- [61] Bury F, Igyuovwe V, Trivett M, Baraitser P. Patterns of use of emergency and oral contraceptives from an online service in the United Kingdom during the COVID-19 pandemic: a quantitative study of routinely collected data. *Contraception* 2023;122. <https://doi.org/10.1016/j.contraception.2023.109992>
- [62] Zuniga C, Grossman D, Harrell S, Blanchard K, Grindlay K. Breaking down barriers to birth control access: an assessment of online platforms prescribing birth control in the USA. *J Telemed Telecare* 2020;26:322–31. <https://doi.org/10.1177/1357633x18824828>
- [63] Society of Family Planning Interim Clinical Recommendations self-managed abortion. The Society of Family Planning; 2022. <https://doi.org/10.46621/ZRDX9581>
- [64] American College of Obstetricians and Gynecologists. ACOG Committee Statement No. 13: self-managed abortion. *Obstet Gynecol* 2024;144:e152–9. <https://doi.org/10.1097/AOG.0000000000005755>
- [65] Sundstrom B, DeMaria AL, Ferrara M, Meier S, Billings D. "The closer, the better": the role of telehealth in increasing contraceptive access among women in rural South Carolina. *Matern Child Health J* 2019;23:1196–205. <https://doi.org/10.1007/s10995-019-02750-3>
- [66] Footman K. Revolution in abortion care? Perspectives of key informants on the importance of abortion method choice in the era of telemedicine. *Sex Reprod Health Matters* 2023;31. <https://doi.org/10.1080/26410397.2022.2149379>
- [67] Blaylock R, Lohr PA, Hoggart L, Lowe P. Patient experiences of undergoing abortion with and without an ultrasound scan in Britain. *BMJ Sex Reprod Health* 2024;50:178–84. <https://doi.org/10.1136/bmjsexrh-2023-202116>
- [68] Reynolds-Wright JJ, Johnstone A, McCabe K, Evans E, Cameron S. Telemedicine medical abortion at home under 12 weeks' gestation: a prospective observational cohort study during the COVID-19 pandemic. *BMJ Sex Reprod Health* 2021;47:246–51. <https://doi.org/10.1136/bmjsexrh-2020-200976>
- [69] Podolskiy V, Gemzell-Danielsson K, Marions L, Gomperts R. Preabortion ultrasound – a patient perspective. *Eur J Contracept Reprod Health Care Off J Eur Soc Contracept* 2023;28:268–73. <https://doi.org/10.1080/13625187.2023.2249158>
- [70] Oppegaard KS, Qvigstad E, Fiala C, Heikinheimo O, Benson L, Gemzell-Danielsson K. Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. *The Lancet* 2015;385:698–704. [https://doi.org/10.1016/S0140-6736\(14\)61054-0](https://doi.org/10.1016/S0140-6736(14)61054-0)
- [71] Bracken H, Lohr PA, Taylor J, Morroni C, Winikoff B. RU OK? The acceptability and feasibility of remote technologies for follow-up after early medical abortion. *Contraception* 2014;90:29–35. <https://doi.org/10.1016/j.contraception.2014.03.016>
- [72] Platais I, Tsereteli T, Comendant R, Kurbanbekova D, Winikoff B. Acceptability and feasibility of phone follow-up with a semiquantitative urine pregnancy test after medical abortion in Moldova and Uzbekistan. *Contraception* 2015;91:178–83. <https://doi.org/10.1016/j.contraception.2014.11.004>
- [73] Ngoc NTN, Bracken H, Blum J, Nga NTB, Minh NH, Van Nhang N, et al. Acceptability and feasibility of phone follow-up after early medical abortion in Vietnam: a randomized controlled trial. *Obstet Gynecol* 2014;123:88–95. <https://doi.org/10.1097/AOG.0000000000000505>
- [74] Kapp N, Mao B, Menzel J, Eckersberger E, Saphonn V, Rathavy T, et al. A prospective, comparative study of clinical outcomes following clinic-based versus self-use of medical abortion. *BMJ Sex Reprod Health* 2023. <https://doi.org/10.1136/bmjsexrh-2022-201722>
- [75] Kavanaugh ML, Zolna MR. Where do reproductive-aged women want to get contraception? *J Womens Health* 2023;32:657–69. <https://doi.org/10.1089/jwh.2022.0406>
- [76] Hurtado ACM, Crowley SM, Landry KM, Landry MS. Telehealth contraceptive care in 2018: a quality improvement study of barriers to access and patient satisfaction. *Contraception* 2022;112:81–5. <https://doi.org/10.1016/j.contraception.2022.02.011>

- [77] Maier MC, Gold MA, Vacca SH, Garbers S. Mixed-methods exploration of telehealth-supported long-acting reversible contraceptive services in school-based health centers: how much added value? *J Pediatr Health Care* 2023. <https://doi.org/10.1016/j.pedhc.2023.05.004>
- [78] Brandi K, Woodhams E, White KO, Mehta PK. An exploration of perceived contraceptive coercion at the time of abortion. *Contraception* 2018;97:329–34. <https://doi.org/10.1016/j.contraception.2017.12.009>
- [79] Gutman S, Connor H, Mumford SL, Gilmore E, Roe AH, Schreiber CA. Feasibility and acceptability of virtual group contraceptive counseling prior to abortion care. *Contraception* 2023. <https://doi.org/10.1016/j.contraception.2023.110114>
- [80] Lohr PA, Aiken ARA, Forsyth T, Trussell J. Telephone or integrated contraception counselling before abortion: impact on method choice and receipt. *BMJ Sex Reprod Health* 2018;44:114–21. <https://doi.org/10.1136/bmjsexrh-2017-101818>
- [81] Dixon A, Reynolds-Wright JJ, Cameron ST. Uptake of long-acting reversible contraception after telemedicine delivered abortion during COVID-19. *Eur J Contracept Reprod Health Care* 2022;27:284–8. <https://doi.org/10.1080/13625187.2022.2085680>
- [82] Monardez Popelka JP, Garcia-Huidobro D, Svetaz MV, Gewirtz O'Brien JO, Sixberry RC. 89. Telemedicine: is it the best solution for teenagers looking for reproductive health services? *J Adolesc Health* 2022;70:S47. <https://doi.org/10.1016/j.jadohealth.2022.01.184>
- [83] Bakhai M, Perera S. Review: use of digital sexual health services by under-16s and an evaluation of safeguarding procedures. *Sex Transm Infect* 2017;93:A58. <https://doi.org/10.1136/sextans-2017-053232.169>
- [84] Reilly K, Ebersole A. Confidentiality and privacy considerations for adolescents receiving contraceptive health services via telemedicine: a narrative review. *Womens Health* 2024;20:17455057241233126. <https://doi.org/10.1177/17455057241233126>
- [85] Yarger J, Hopkins K, Elmes S, Rossetto I, Van Liefde D, De La Melena S, et al. Use of telemedicine to obtain contraception among young adults: inequities by health insurance. *Contraception* 2024;134:110419. <https://doi.org/10.1016/j.contraception.2024.110419>
- [86] Fiastro AE, Sanan S, Jacob-Files E, Wells E, Coeytaux F, Ruben MR, et al. Remote delivery in reproductive health care: operation of direct-to-patient telehealth medication abortion services in diverse settings. *Ann Fam Med* 2022;20:336–42. <https://doi.org/10.1370/afm.2821>
- [87] Baraitser P, Free C, Norman WV, Lewandowska M, Meiksin R, Palmer MJ, et al. Improving experience of medical abortion at home in a changing therapeutic, technological and regulatory landscape: a realist review. *BMJ Open* 2022;12:e066650. <https://doi.org/10.1136/bmjopen-2022-066650>
- [88] Jain D, Davies M, Perritt J, Blasdell J. The provision of medication abortion care via telehealth. *Womens Health Issues Off Publ Jacobs Inst Womens Health* 2023. <https://doi.org/10.1016/j.whi.2023.04.008>
- [89] Matulich MC, Hou MY, Chen MJ, Uhm S, Creinin MD. Implementation of telemedicine preoperative visits for abortion procedures through 18 weeks gestation at a Northern California hospital-based center. *Contraception* 2022;114:74–8. <https://doi.org/10.1016/j.contraception.2022.06.001>
- [90] Godfrey EM, Fiastro AE, Jacob-Files EA, Coeytaux FM, Wells ES, Ruben MR, et al. Factors associated with successful implementation of telehealth abortion in 4 United States clinical practice settings. *Contraception* 2021;104:82–91. <https://doi.org/10.1016/j.contraception.2021.04.021>
- [91] Reynolds-Wright JJ, Boydell N, Cameron S, Harden J. A qualitative study of abortion care providers' perspectives on telemedicine medical abortion provision in the context of COVID-19. *BMJ Sex Reprod Health* 2022;48:199–204. <https://doi.org/10.1136/bmjsexrh-2021-201309>
- [92] Batalova J, Zong J. Language diversity and english proficiency in the United States. *Online J Migr Policy Inst* 2016.
- [93] Anawade PA, Sharma D, Gahane S. A comprehensive review on exploring the impact of telemedicine on healthcare accessibility. *Cureus* 2024. <https://doi.org/10.7759/cureus.55996>
- [94] Anastario M, FireMoon P, Ricker A, Holder S, Rink E. Self-reported exposure to sexual and reproductive health information among American Indian Youth: implications for technology based intervention. *J Health Commun* 2020;25:412–20. <https://doi.org/10.1080/10810730.2020.177599>
- [95] Petretto DR, Carrogu GP, Gaviano L, Berti R, Pinna M, Petretto AD, et al. Telemedicine, e-health, and digital health equity: a scoping review. *Clin Pract Epidemiol Ment Health* 2024;20:e17450179279732. <https://doi.org/10.2174/011745017927973223121110248>
- [96] Arey W, Lerma K, Carpenter E, Moayedi G, Harper L, Beasley A, et al. Abortion access and medically complex pregnancies before and after Texas Senate Bill 8. *Obstet Gynecol* 2023. <https://doi.org/10.1097/AOG.0000000000005153>
- [97] Harris LH, Grossman D. Complications of unsafe and self-managed abortion. *N Engl J Med* 2020;382:1029–40. <https://doi.org/10.1056/NEJMr1908412>
- [98] Rader B, Upadhyay UD, Sehgal NKR, Reis BY, Brownstein JS, Hswen Y. Estimated travel time and spatial access to abortion facilities in the US before and after the *Dobbs v Jackson Women's Health* Decision. *JAMA* 2022;328:2041. <https://doi.org/10.1001/jama.2022.20424>
- [99] Rodriguez JA, Betancourt J, Sequist T, Ganguli I. Differences in the use of telephone and video telemedicine visits during the COVID-19 pandemic. *Am J Manag Care* 2021;27:21–6. <https://doi.org/10.37765/ajmc.2021.88573>
- [100] Thompson T-A, Northcraft D, Carrión F. Addressing structural inequities, a necessary step toward ensuring equitable access to telehealth for medication abortion care during and post COVID-19. *Front Glob Womens Health* 2022;3:805767. <https://doi.org/10.3389/fgwh.2022.805767>
- [101] Meurice ME, Mody SK, Nodora J, Marengo A, Averbach S. Social determinants of choosing telemedicine for contraceptive care: a retrospective cohort study. *Contraception* 2024;134:110414. <https://doi.org/10.1016/j.contraception.2024.110414>
- [102] Merz-Herrala AA, Kerns JL, Logan R, Gutierrez S, Marshall C, Diamond-Smith N. Contraceptive care in the United States during the COVID-19 pandemic: a social media survey of contraceptive access, telehealth use and telehealth quality. *Contraception* 2023;123. <https://doi.org/10.1016/j.contraception.2023.110000>
- [103] Hill BJ, Lock L, Anderson B. Racial and ethnic differences in family planning medication use during the onset of the COVID-19 response in Arkansas, Kansas, Missouri, and Oklahoma. *Contraception* 2021;104:262–4. <https://doi.org/10.1016/j.contraception.2021.05.016>
- [104] ACOG Committee Opinion No. 613: increasing access to abortion. *Obstet Gynecol* 2014;124:1060–5. <https://doi.org/10.1097/01.AOG.0000456326.88857.31>
- [105] Kortsmit K, Nguyen AT, Mandel MG, Hollier LM, Ramer S, Rodenhizer J, et al. Abortion surveillance - United States, 2021. *Morb Mortal Wkly Rep Surveill Summ Wash DC* 2002 2023;72:1–29. <https://doi.org/10.15585/mmwr.mm7209a1>
- [106] Jerman J, Jones RK, Onda T. Characteristics of U.S. abortion patients in 2014 and changes since 2008. New York: Guttmacher Institute; 2016.
- [107] Shaw J, Brewer LC, Veinot T. Recommendations for health equity and virtual care arising from the COVID-19 pandemic: narrative review. *JMIR Form Res* 2021;5:e23233. <https://doi.org/10.2196/23233>
- [108] Yarger J, Hopkins K, Elmes S, Rossetto I, De La Melena S, McCulloch CE, et al. Perceived access to contraception via telemedicine among young adults: inequities by food and housing insecurity. *J Gen Intern Med* 2023;38:302–8. <https://doi.org/10.1007/s11606-022-07669-0>
- [109] Pierce RP, Stevermer JJ. Disparities in the use of telehealth at the onset of the COVID-19 public health emergency. *J Telemed Telecare* 2023;29:3–9. <https://doi.org/10.1177/1357633x20963893>
- [110] Weber E, Miller SJ, Astha V, Janevic T, Benn E. Characteristics of telehealth users in NYC for COVID-related care during the coronavirus pandemic. *J Am Med Inform Assoc* 2020;27:1949–54. <https://doi.org/10.1093/jamia/ocaa216>
- [111] Chidambaram S, Jain B, Jain U, Mwavu R, Baru R, Thomas B, et al. An introduction to digital determinants of health. *PLOS Digit Health* 2024;3:e0000346. <https://doi.org/10.1371/journal.pdig.0000346>
- [112] Tukur M, Saad G, AlShagathrh FM, Househ M, Agus M. Telehealth interventions during COVID-19 pandemic: a scoping review of applications, challenges, privacy and security issues. *BMJ Health Care Inform* 2023;30:e100676. <https://doi.org/10.1136/bmjhci-2022-100676>
- [113] Perrin A. Mobile technology and home broadband 2021. *Pew Research Center*; 2021.
- [114] Brakman A, Ellsworth TR, Gold M. Telehealth improves access to reproductive health education and services for rural adolescents. *Contracept Technol Update* 2017;38:70–1.
- [115] Hoopes AJ, Maslowsky J, Baca MA, Goldberg J, Harrison ME, Hwang LY, et al. Elevating the needs of minor adolescents in a landscape of reduced abortion access in the United States. *J Adolesc Health* 2022;71:530–2. <https://doi.org/10.1016/j.jadohealth.2022.08.007>
- [116] Beatty K, Smith MG, Khoury AJ, Ventura LM, Ariyo O, de Jong J, et al. Contraceptive care service provision via telehealth early in the COVID-19 pandemic at rural and urban federally qualified health centers in 2 southeastern states. *J Rural Health* 2023;39:160–71. <https://doi.org/10.1111/jrjh.12701>
- [117] Scott Kruse C, Karem P, Shifflett K, Vegi L, Ravi K, Brooks M. Evaluating barriers to adopting telemedicine worldwide: a systematic review. *J Telemed Telecare* 2018;24:4–12. <https://doi.org/10.1177/1357633x16674087>
- [118] Gabriela Weigel, Frederiksen B. Telemedicine in sexual and reproductive health. *KFF*; 2019.
- [119] Duffy Cat. Progress and gaps in medicaid coverage of telehealth medication abortion services in six states. *National Health Law Program*; 2022.
- [120] Chang JE, Lai AY, Gupta A, Nguyen AM, Berry CA, Shelley DR. Rapid transition to telehealth and the digital divide: implications for primary care access and equity in a post-COVID era. *Milbank Q* 2021;99:340–68. <https://doi.org/10.1111/1468-0009.12509>
- [121] Rao L, Comfort AB, Dojiri SS, Goodman S, Yarger J, Shah N, et al. Telehealth for contraceptive services during the COVID-19 pandemic: provider perspectives. *Womens Health Issues* 2022;32:477–83. <https://doi.org/10.1016/j.whi.2022.05.001>
- [122] Clayton EW, Embi PJ, Malin BA. Dobbs and the future of health data privacy for patients and healthcare organizations. *J Am Med Inform Assoc JAMIA* 2022;30:155–60. <https://doi.org/10.1093/jamia/ocac155>
- [123] Brown EM, Gewirtz O'Brien JR, Monardez Popelka JP, Argo TA, Hogan MJ, Svetaz MV. 104. Telemedicine for teens: can we confidently deliver effective and equitable care? *J Adolesc Health* 2021;68:S55. <https://doi.org/10.1016/j.jadohealth.2020.12.113>
- [124] Protecting confidentiality for individuals insured as dependents. *Guttman Institute*; 2023.
- [125] Parental involvement in minors' abortions. *Guttman Institute*; 2023.
- [126] Upadhyay UD, Koenig LR, Meckstroth K, Ko J, Valladares ES, Biggs MA. Effectiveness and safety of telehealth medication abortion in the USA. *Nat Med* 2024;30:1191–8. <https://doi.org/10.1038/s41591-024-02834-w>
- [127] Map of State Laws Impacting Telehealth for Medication Abortion Care (TMAB). *RHITES* n.d. (<https://www.rhites.org/tmab-map>) (accessed July 26, 2024).
- [128] Marblestone C. Medication abortion, telemedicine, and Dobbs—key considerations for healthcare providers. *Pract Guid J* 2022 (<https://www.lexisnexis.com/community/insights/legal/practical-guidance-journal/b/pa/posts/medication-abortion-telemedicine-and-dobbs-key-considerations-for-healthcare-providers>).